德国首例耐泰利霉素肺炎链球菌分离株的分子特征分析
Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany.
作者信息
Reinert Ralf René, van der Linden Mark, Al-Lahham Adnan
机构信息
Institute for Medical Microbiology, National Reference Center for Streptococci, University Hospital, Pauwelsstrasse 30, D-52057 Aachen, Germany.
出版信息
Antimicrob Agents Chemother. 2005 Aug;49(8):3520-2. doi: 10.1128/AAC.49.8.3520-3522.2005.
Abstract
A total of 486 Streptococcus pneumoniae isolates were collected in 2003 and 2004 in Germany and revealed the following resistance rates: penicillin G (7.2%) and erythromycin A (18.9%). Telithromycin exhibited good in vitro activity (MIC at which 90% of the isolates tested were inhibited, 0.125 microg/ml). However, one erm(B)-positive isolate was found to be telithromycin resistant (MIC, 8 microg/ml).
摘要
2003年和2004年在德国共收集了486株肺炎链球菌分离株，其耐药率如下：青霉素G（7.2%）和红霉素A（18.9%）。替利霉素表现出良好的体外活性（90%受试分离株被抑制时的最低抑菌浓度，0.125微克/毫升）。然而，发现一株erm(B)阳性分离株对替利霉素耐药（最低抑菌浓度，8微克/毫升）。
相似文献
1
Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany.德国首例耐泰利霉素肺炎链球菌分离株的分子特征分析
Antimicrob Agents Chemother. 2005 Aug;49(8):3520-2. doi: 10.1128/AAC.49.8.3520-3522.2005.
2
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.16元环大环内酯类药物及泰利霉素对不同基因型的红霉素敏感及耐药化脓性链球菌和肺炎链球菌的活性。
J Antimicrob Chemother. 2007 Jun;59(6):1171-6. doi: 10.1093/jac/dkm089. Epub 2007 Apr 3.
3
High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.2000 - 2001年冬季德国耐红霉素肺炎链球菌分离株中ermB基因的高流行率及泰利霉素的体外活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3193-5. doi: 10.1128/AAC.48.8.3193-3195.2004.
4
Macrolide-resistance mechanisms in Streptococcus pneumoniae isolates from Belgium.比利时肺炎链球菌分离株中的大环内酯类耐药机制
Clin Microbiol Infect. 2005 Apr;11(4):332-4. doi: 10.1111/j.1469-0691.2005.01077.x.
5
Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae.韩国耐红霉素肺炎链球菌的特征以及泰利霉素对耐红霉素肺炎链球菌的体外活性
Microb Drug Resist. 2005 Fall;11(3):260-5. doi: 10.1089/mdr.2005.11.260.
6
Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.模拟临床可达到的游离血清和上皮衬液浓度时，泰利霉素对大环内酯类敏感和耐药肺炎链球菌的药效学活性。
J Antimicrob Chemother. 2004 Dec;54(6):1072-7. doi: 10.1093/jac/dkh475. Epub 2004 Nov 5.
7
Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.1998 - 1999年加拿大耐大环内酯类肺炎链球菌：mef(A)和erm(B)的流行情况以及对酮内酯类的敏感性
Antimicrob Agents Chemother. 2001 Jul;45(7):2147-50. doi: 10.1128/AAC.45.7.2147-2150.2001.
8
Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.化脓性链球菌和肺炎链球菌对大环内酯类药物及泰利霉素的敏感性：一项意大利多中心研究的数据。
J Chemother. 2007 Oct;19(5):500-7. doi: 10.1179/joc.2007.19.5.500.
9
Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital.从阿根廷一家教学医院的社区获得性肺炎成年患者中分离出的大环内酯类耐药肺炎链球菌的表型和基因型特征
Int J Antimicrob Agents. 2005 Mar;25(3):260-3. doi: 10.1016/j.ijantimicag.2004.10.011. Epub 2005 Jan 21.
10
[In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study].[肺炎链球菌和化脓性链球菌呼吸道分离株对泰利霉素及其他11种抗菌药物的体外敏感性：e-BASKETT-II监测研究的土耳其结果]
Mikrobiyol Bul. 2007 Jan;41(1):1-9.
引用本文的文献
1
Synthesis and SARs of novel lincomycin derivatives Part 5: optimization of lincomycin analogs exhibiting potent antibacterial activities by chemical modification at the 6- and 7-positions.新型林可霉素衍生物的合成及构效关系研究 第 5 部分：通过化学修饰 6-位和 7-位对具有强抗菌活性的林可霉素类似物进行优化。
J Antibiot (Tokyo). 2018 Feb;71(2):298-317. doi: 10.1038/ja.2017.114. Epub 2017 Nov 1.
2
Synthesis and structure-activity relationships of novel lincomycin derivatives. Part 4: synthesis of novel lincomycin analogs modified at the 6- and 7-positions and their potent antibacterial activities.新型林可霉素衍生物的合成及其构效关系。第4部分：6位和7位修饰的新型林可霉素类似物的合成及其强效抗菌活性。
J Antibiot (Tokyo). 2017 Jul;70(8):888-906. doi: 10.1038/ja.2017.54. Epub 2017 May 31.
3
Synthesis and structure-activity relationships of novel lincomycin derivatives part 3: discovery of the 4-(pyrimidin-5-yl)phenyl group in synthesis of 7(S)-thiolincomycin analogs.新型林可霉素衍生物的合成及其构效关系 第3部分：7(S)-硫代林可霉素类似物合成中4-(嘧啶-5-基)苯基的发现
J Antibiot (Tokyo). 2017 Jan;70(1):52-64. doi: 10.1038/ja.2016.114. Epub 2016 Oct 5.
4
Resistance to Macrolide Antibiotics in Public Health Pathogens.公共卫生病原体对大环内酯类抗生素的耐药性
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):a025395. doi: 10.1101/cshperspect.a025395.
5
Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.结合疫苗时代前后美国耐抗生素肺炎链球菌的生物学和流行病学特征
Clin Microbiol Rev. 2016 Jul;29(3):525-52. doi: 10.1128/CMR.00058-15.
6
Synthesis and structure-activity relationships of novel lincomycin derivatives. Part 1. Newly generated antibacterial activities against Gram-positive bacteria with erm gene by C-7 modification.新型林可霉素衍生物的合成及其构效关系。第1部分。通过C-7修饰对携带erm基因的革兰氏阳性菌产生的新抗菌活性。
J Antibiot (Tokyo). 2016 May;69(5):368-80. doi: 10.1038/ja.2015.119. Epub 2015 Dec 16.
7
Synthesis and structure-activity relationships of novel lincomycin derivatives. Part 2. Synthesis of 7(S)-7-deoxy-7-(4-morpholinocarbonylphenylthio)lincomycin and its 3-dimensional analysis with rRNA.新型林可霉素衍生物的合成及其构效关系。第2部分。7(S)-7-脱氧-7-(4-吗啉代羰基苯硫基)林可霉素的合成及其与rRNA的三维分析
J Antibiot (Tokyo). 2016 Jun;69(6):428-39. doi: 10.1038/ja.2015.125. Epub 2015 Dec 16.
8
Methylation of 23S rRNA nucleotide G748 by RlmAII methyltransferase renders Streptococcus pneumoniae telithromycin susceptible.RlmAII 甲基转移酶对 23S rRNA 核苷酸 G748 的甲基化使肺炎链球菌对替利霉素敏感。
Antimicrob Agents Chemother. 2013 Aug;57(8):3789-96. doi: 10.1128/AAC.00164-13. Epub 2013 May 28.
9
Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation.肺炎链球菌对泰利霉素的耐药性是由erm(B)前导序列中的缺失导致的，该缺失增加了rRNA甲基化。
Antimicrob Agents Chemother. 2008 Feb;52(2):435-40. doi: 10.1128/AAC.01074-07. Epub 2007 Dec 3.
10
Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal.葡萄牙侵袭性肺炎球菌对青霉素和红霉素的耐药性趋势。
Epidemiol Infect. 2008 Jul;136(7):928-39. doi: 10.1017/S0950268807009405. Epub 2007 Aug 16.
本文引用的文献
1
Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe.欧洲大环内酯类耐药肺炎链球菌分离株的分子流行病学
J Clin Microbiol. 2005 Mar;43(3):1294-300. doi: 10.1128/JCM.43.3.1294-1300.2005.
2
Molecular characterisation of macrolide resistance mechanisms of Streptococcus pneumoniae and Streptococcus pyogenes isolated in Germany, 2002-2003.2002 - 2003年德国分离的肺炎链球菌和化脓性链球菌大环内酯类耐药机制的分子特征
Int J Antimicrob Agents. 2004 Jul;24(1):43-7. doi: 10.1016/j.ijantimicag.2004.02.020.
3
Clinical efficacy of ketolides in the treatment of respiratory tract infections.酮内酯类药物治疗呼吸道感染的临床疗效
J Antimicrob Chemother. 2004 Jun;53(6):918-27. doi: 10.1093/jac/dkh169. Epub 2004 Apr 29.
4
Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.泰利霉素对1999年至2003年间收集的13874株肺炎链球菌的活性。
Antimicrob Agents Chemother. 2004 May;48(5):1882-4. doi: 10.1128/AAC.48.5.1882-1884.2004.
5
Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany.在德国分离出的肺炎链球菌临床菌株中赋予对大环内酯类抗生素耐药性的核糖体突变。
Antimicrob Agents Chemother. 2003 Jul;47(7):2319-22. doi: 10.1128/AAC.47.7.2319-2322.2003.
6
Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae.肺炎链球菌对四环素和红霉素耐药菌株的表型及分子特征
Antimicrob Agents Chemother. 2003 Jul;47(7):2236-41. doi: 10.1128/AAC.47.7.2236-2241.2003.
7
Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.来自PROTEKT监测研究的肺炎链球菌分离株中抗菌药物耐药性的患病率不断上升，以及酮内酯类药物泰利霉素的体外比较活性。
J Antimicrob Chemother. 2002 Sep;50 Suppl S1:25-37. doi: 10.1093/jac/dkf808.
8
Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.德国侵袭性肺炎球菌分离株中大环内酯类和青霉素耐药性的出现。
J Antimicrob Chemother. 2002 Jan;49(1):61-8. doi: 10.1093/jac/49.1.61.
9
Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.肺炎链球菌中赋予对大环内酯类、克林霉素、链阳菌素和替利霉素耐药性的核糖体突变的多样性。
Antimicrob Agents Chemother. 2002 Jan;46(1):125-31. doi: 10.1128/AAC.46.1.125-131.2002.
10
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study.1998年至1999年德国门诊呼吸道感染患者中分离出的肺炎链球菌的耐药性：一项全国性监测研究的结果
J Clin Microbiol. 2001 Mar;39(3):1187-9. doi: 10.1128/JCM.39.3.1187-1189.2001.
Zotero 插件